MX2023004829A - Compuestos, composiciones y metodos de uso para tratar fusiones espinales. - Google Patents
Compuestos, composiciones y metodos de uso para tratar fusiones espinales.Info
- Publication number
- MX2023004829A MX2023004829A MX2023004829A MX2023004829A MX2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- compositions
- treat spinal
- spinal fusions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105678P | 2020-10-26 | 2020-10-26 | |
| US202163193753P | 2021-05-27 | 2021-05-27 | |
| PCT/US2021/047827 WO2022093374A1 (en) | 2020-10-26 | 2021-08-26 | Compounds,compositions and methods of use to treat spinal fusions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004829A true MX2023004829A (es) | 2023-07-18 |
Family
ID=81383097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004829A MX2023004829A (es) | 2020-10-26 | 2021-08-26 | Compuestos, composiciones y metodos de uso para tratar fusiones espinales. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230390363A1 (https=) |
| EP (1) | EP4232075A4 (https=) |
| JP (1) | JP2023547889A (https=) |
| AU (1) | AU2021369193A1 (https=) |
| CA (1) | CA3196688A1 (https=) |
| MX (1) | MX2023004829A (https=) |
| WO (1) | WO2022093374A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019232285A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
| EP4719459A1 (en) * | 2023-06-01 | 2026-04-08 | Radius Health, Inc. | Methods for identification and quantitation of abaloparatide and related peptide impurities |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| EP3765488A1 (en) * | 2018-03-12 | 2021-01-20 | Fresenius Kabi iPSUM S.r.l. | Process for the manufacture of pthrp analogue |
| WO2019232285A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
-
2021
- 2021-08-26 WO PCT/US2021/047827 patent/WO2022093374A1/en not_active Ceased
- 2021-08-26 CA CA3196688A patent/CA3196688A1/en active Pending
- 2021-08-26 EP EP21887114.3A patent/EP4232075A4/en active Pending
- 2021-08-26 AU AU2021369193A patent/AU2021369193A1/en active Pending
- 2021-08-26 MX MX2023004829A patent/MX2023004829A/es unknown
- 2021-08-26 US US18/033,658 patent/US20230390363A1/en active Pending
- 2021-08-26 JP JP2023525023A patent/JP2023547889A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022093374A1 (en) | 2022-05-05 |
| CA3196688A1 (en) | 2022-05-05 |
| WO2022093374A8 (en) | 2022-09-29 |
| JP2023547889A (ja) | 2023-11-14 |
| AU2021369193A1 (en) | 2023-06-01 |
| EP4232075A4 (en) | 2024-12-18 |
| US20230390363A1 (en) | 2023-12-07 |
| EP4232075A1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004829A (es) | Compuestos, composiciones y metodos de uso para tratar fusiones espinales. | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2024006824A (es) | Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos. | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| SA522433087B1 (ar) | Sos1 مثبطات | |
| PH12021551409A1 (en) | Kif18a inhibitors | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| MX2021005887A (es) | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| MX2020008767A (es) | Disruptores del dímero egfr y uso de estos. | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| BR112016016870A2 (pt) | Derivados de icariina, seus usos, e composição farmacêutica | |
| PH12017502123A1 (en) | Substituted benzamides and methods of use thereof | |
| PH12018502337A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| MX2023004796A (es) | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. | |
| MX385698B (es) | Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| PH12022551371A1 (en) | Macrocycles for use in treating disease | |
| GEAP202516674A (en) | Indazole macrocycles and their use |